Aaron Karr, DO
Family Medicine · Sheffield, ALNPI 1265428031
Payments from drug & device makers
Across 324 payments — averaging $9469.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$1.8M
- AstraZeneca$1M
- Amgen$115K
- Sanofi$30K
- Novartis$20K
- Chiesi USA, Inc.$15K
- plus $42K from 27 others
Across 9 payments — averaging $6329.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$57K
What the payments were for
- Speaking & faculty fees$8,00062%
- Food & beverage$4,80138%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 47 | $1,817,659 |
| AstraZeneca | 28 | $1,028,630 |
| Amgen | 2 | $115,357 |
| Sanofi | 5 | $29,506 |
| Novartis | 2 | $20,427 |
| Chiesi USA, Inc. | 4 | $15,043 |
| Alnylam Pharmaceuticals Inc. | 2 | $13,000 |
| GSK | 74 | $11,462 |
| Indivior Inc. | 49 | $8,666 |
| Astrazeneca UK Limited | 1 | $3,933 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $2,000 |
| Insulet Corporation | 3 | $709 |
| Novo Nordisk | 28 | $548 |
| AbbVie(2 entities) | 21 | $335 |
| Lilly USA, LLC | 8 | $110 |
| Merck | 7 | $93 |
| Johnson & Johnson | 6 | $81 |
| Eisai Inc. | 1 | $75 |
| Corcept Therapeutics | 4 | $70 |
| Amarin Pharma, Inc. | 4 | $64 |
| Otsuka America Pharmaceutical, Inc. | 4 | $61 |
| Pfizer | 4 | $53 |
| Roche Diagnostics Corporation | 1 | $50 |
| Orexo US, Inc. | 3 | $42 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $41 |
| Boehringer Ingelheim | 2 | $32 |
| Alkermes, Inc. | 1 | $27 |
| Phathom Pharmaceuticals, Inc. | 4 | $24 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Irhythm Technologies, Inc. | 1 | $14 |
| Ironwood Pharmaceuticals, Inc | 1 | $13 |
| Astellas Pharma US Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,068,173 in reported general payments places this provider in the 95th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 102 | $118,274 |
| OzempicSemaglutide | 61 | $64,358 |
| TrulicityDulaglutide | 57 | $63,741 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 71 | $58,496 |
| FarxigaDapagliflozin Propanediol | 68 | $57,768 |
| JardianceEmpagliflozin | 63 | $55,088 |
| EliquisApixaban | 62 | $47,778 |
| JanuviaSitagliptin Phosphate | 41 | $43,928 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 237 | $34,983 |
| LinzessLinaclotide | 33 | $32,699 |
| RexultiBrexpiprazole | 12 | $17,135 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 40 | $16,617 |
| XareltoRivaroxaban | 14 | $15,030 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 774 | $13,723 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 26 | $12,629 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $110 | $182,016159 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,028,630 | $70,39495 claims |
| Novo NordiskOzempic | $548 | $64,35861 claims |
| MerckJanuvia, Janumet, Belsomra | $93 | $62,04873 claims |
| GSKTrelegy Ellipta | $11,462 | $58,49671 claims |
| Boehringer IngelheimJardiance | $32 | $55,08863 claims |
| PfizerEliquis, Dilantin | $53 | $50,04174 claims |
| AbbVieLinzess | $335 | $32,69933 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $61 | $17,13512 claims |
| Orexo US, Inc.Zubsolv | $42 | $16,61740 claims |
| Johnson & JohnsonXarelto | $81 | $15,03014 claims |
| Indivior Inc.Suboxone | $8,666 | $12,62926 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Sheffield
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
- Nidal MorrarFoley$3M
- Timothy HowardHuntsville$3M
- David WeverPelham$2.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.